Exjade will be the first ORAL iron-chelation therapy

Exjade will be the first ORAL iron-chelation therapy.

It's investigational in Canada and just approved in the U.S.

Patients who need blood transfusions for sickle cell disease, thalassemia, and other blood disorders often develop iron overload.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote